Touami Sofia, the Chief Business Officer of Lycia Therapeutics, Inc., has filed a report detailing her ownership of stock options in the company. This filing is significant as it underscores her involvement in the firm and highlights the potential for future financial interests tied to the company's performance.
Lycia Therapeutics, Inc., incorporated in Delaware, operates in the biological products sector, specifically focusing on non-diagnostic substances. The company is listed under the Central Index Key (CIK) 0001806540. Its fiscal year ends on December 31st, and it is based in South San Francisco, California.
The filing, made on October 22, 2026, indicates that Sofia does not currently own any shares outright but holds stock options that allow her to purchase shares at predetermined prices. Specifically, she has options for 169,228 shares at an exercise price of $1.67, 94,262 shares at $2.44, and 68,755 shares at $3.70. These options are set to expire between 2033 and 2036, with various vesting schedules that require her continued service with the company.
The details of these stock options may impact investor perceptions and decisions regarding Lycia Therapeutics, especially considering the competitive landscape in the biological products industry. As a key officer, Sofia's financial interests could align with the company's growth and success, potentially influencing strategic decisions.
What’s next for Sofia and Lycia Therapeutics remains unclear, as the filing does not specify any upcoming events or further disclosures.